Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US-10526419-B2 · Jan 7, 2020 · US
Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities
US11078299B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11078299-B2 |
| Application number | US-202016842195-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 7, 2020 |
| Priority date | Mar 16, 2009 |
| Publication date | Aug 3, 2021 |
| Grant date | Aug 3, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a viral respiratory infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition, comprising a physiologically acceptable carrier and a fusion polypeptide, wherein the fusion polypeptide comprises a histidyl-tRNA synthetase (HRS) polypeptide fused to an Fc fragment, wherein the FIRS polypeptide consists of a sequence that has at least 95% identity along its length to SEQ ID NO: 6, comprises a WHEP domain, and lacks a functional aminoacylation domain. 2. The method of claim 1 , wherein the FIRS polypeptide consists of a sequence that has at least 98% identity along its length to SEQ ID NO: 6. 3. The method of claim 1 , wherein the N-terminal region of the HRS polypeptide polypeptide is truncated by 1, 2, or 3 amino acids. 4. The method of claim 1 , wherein the fusion polypeptide reduces cell migration of monocytes/macrophages in the subject in need thereof. 5. The method of claim 1 , comprising intravenously administering the pharmaceutical composition to the subject. 6. The method of any one of claims 1 - 5 , wherein the viral respiratory infection comprises a Severe Acute Respiratory Syndrome (SARS) infectious agent.
Assignees
Inventors
Classifications
- C12Q1/6886Primary
for cancer (immunoassay for cancer G01N33/575) · CPC title
Drugs for disorders of the cardiovascular system · CPC title
involving cells · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Polymorphic or mutational markers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11078299B2 cover?
- Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).